Myeloid has dosed its first patient in the IMAGINE study, which is a Phase 1/2, multicenter, open-label, dose-escalation and dose cohort expansion clinical trial evaluating MT-101 in patients with refractory or relapsed PTCL. The dose-escalation portion of this Phase 1 study, with and without conditioning therapy, is open and enrolling patients. Once Myeloid establishes the recommended Phase 2 dose, a Phase 2 trial will be initiated to support registration in this patient population.
MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options, that until now has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity. Treatment in these models has been associated with potent phagocytosis responses, the production of inflammatory mediators and delays in tumor progression.
For more information, please visit:
We are actively recruiting patients to participate in clinical trials. If you or your loved one has Peripheral T cell Lymphoma please see more information about the study below: